Skip to main content

Advertisement

SpringerLink
Log in

Post-Operative Radiation Therapy (PORT) in Completely Resected Non-Small-Cell Lung Cancer

  • Lung Cancer
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

High-level evidence to guide the optimal postoperative management of patients with completely resected non-small-cell lung cancer (NSCLC) is lacking. Large randomized controlled trials have established postoperative chemotherapy as the standard of care for patients with pathologically involved lymph nodes. Recent retrospective and non-randomized studies provide evidence of the benefit of post-operative radiation therapy (PORT) in patients with mediastinal nodal involvement (N2 stage). A large multi-institutional randomized trial of PORT in this patient population is now underway. Based on currently available data, PORT may be considered for fit patients with completely resected NSCLC with N2 nodal involvement, preferably after completion of adjuvant chemotherapy. At this point, PORT is not recommended for patients with less than N2 nodal stage. Ideally, modern three-dimensional conformal radiation technique should be used, with attention to normal organ sparing, particularly lung and heart. Appropriate image guidance tools are encouraged to individualize treatment margins, account for breathing-induced motion, and minimize irradiation of normal tissues. The target volume should include at a minimum the bronchial stump, ipsilateral hilum, and involved nodal stations, and covering adjacent mediastinal nodal stations is recommended. A total dose of 50–54 Gy in 1.8–2 Gy fractions is appropriate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest 2006,130:1791–5. doi:10.1378/chest.130.6.1791.

    Article  PubMed  Google Scholar 

  2. Meyers BF, Haddad F, Siegel BA, et al. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg 2006,131:822–9; discussion –9.

    Article  PubMed  Google Scholar 

  3. Koike T, Tsuchiya R, Goya T, et al. Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan. J Thorac Oncol 2007,2:408–13. doi:10.1097/01.JTO.0000268674.02744.f9.

    Article  PubMed  Google Scholar 

  4. Lee PC, Port JL, Korst RJ, et al. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg 2007,84:177–81. doi:10.1016/j.athoracsur.2007.03.081.

    Article  PubMed  Google Scholar 

  5. Herth FJ, Eberhardt R, Krasnik M, Ernst A. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest 2008,133:887–91. doi:10.1378/chest.07-2535.

    Article  PubMed  Google Scholar 

  6. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000,18:2981–9.

    PubMed  CAS  Google Scholar 

  7. Rusch VW, Crowley J, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007,2:603–12. doi:10.1097/JTO.0b013e31807ec803.

    Article  PubMed  Google Scholar 

  8. Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg 2008,86:362–6; discussion 6–7. doi:10.1016/j.athoracsur.2008.04.042.

    Article  PubMed  Google Scholar 

  9. The PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998,352:257–63. doi:10.1016/S0140-6736(98)06341-7.

    Article  Google Scholar 

  10. Van Houtte P, Rocmans P, Smets P, et al. Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys 1980,6:983–6.

    PubMed  Google Scholar 

  11. The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986,315:1377–81.

    Article  Google Scholar 

  12. Wang M, Gu XZ, Yin WB, et al. Randomized clinical trial of postoperative irradiation after surgery for non-small cell lung carcinoma. Chin J Radiat Oncol 1994,3: 39–43.

    CAS  Google Scholar 

  13. Debevec M, Bitenc M, Vidmar S, et al. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): randomised clinical study 1988–1992. Lung Cancer 1996,14:99–107. doi:10.1016/0169-5002(95)00515-3.

    Article  PubMed  CAS  Google Scholar 

  14. Lafitte JJ, Ribet ME, Prévost BM, et al. Postresection irradiation for T2 N0 M0 non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg 1996,62:830–4. doi:10.1016/S0003-4975(96)00507-3.

    Article  PubMed  CAS  Google Scholar 

  15. Stephens RJ, Girling DJ, Bleehen NM, et al. The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer 1996,74:632–9.

    PubMed  CAS  Google Scholar 

  16. Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d’Etude et de Traitement des Cancers Bronchiques. Cancer 1999,86:265–73. doi:10.1002/(SICI)1097-0142(19990715)86:2<265::AID-CNCR10>3.0.CO;2-B.

    Article  PubMed  CAS  Google Scholar 

  17. Mayer R, Smolle-Juettner FM, Szolar D, et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest 1997,112:954–9. doi:10.1378/chest.112.4.954.

    Article  PubMed  CAS  Google Scholar 

  18. Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 2000,47:925–9. doi:10.1016/S0360-3016(00)00509-5.

    PubMed  CAS  Google Scholar 

  19. Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncology 2002,62:11–9.

    Article  PubMed  Google Scholar 

  20. Perry MC, Kohman LJ, Bonner JA, et al. A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734. Clin Lung Cancer 2007,8:268–72. doi:10.3816/CLC.2007.n.005.

    Article  PubMed  CAS  Google Scholar 

  21. Machtay M, Lee JH, Shrager JB, et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 2001,19:3912–7.

    PubMed  CAS  Google Scholar 

  22. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000,343:1217–22. doi:10.1056/NEJM200010263431703.

    Article  PubMed  CAS  Google Scholar 

  23. Bradley JD, Paulus R, Graham MV, et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group—RTOG 9705. J Clin Oncol 2005,23:3480–7. doi:10.1200/JCO.2005.12.120.

    Article  PubMed  CAS  Google Scholar 

  24. Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008,72:695–701. doi:10.1016/j.ijrobp.2008.01.044.

    PubMed  CAS  Google Scholar 

  25. Burdett S, Stewart L, PORT Meta-analysis Group. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 2005,47:81–3. doi:10.1016/j.lungcan.2004.09.010.

    Article  PubMed  Google Scholar 

  26. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006,24:2998–3006. doi:10.1200/JCO.2005.04.6110.

    Article  PubMed  Google Scholar 

  27. Bekelman JE, Rosenzweig KE, Bach PB, Schrag D. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006,66:492–9. doi:10.1016/j.ijrobp.2006.04.032.

    PubMed  Google Scholar 

  28. Wakelee H, Chhatwani L. Adjuvant chemotherapy for resected non-small cell lung cancer. Seminars in Thoracic and Cardiovascular Surgery 2008,20:198–203. doi:10.1053/j.semtcvs.2008.09.001.

    Article  PubMed  Google Scholar 

  29. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004,350:351–60. doi:10.1056/NEJMoa031644.

    Article  PubMed  Google Scholar 

  30. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005,352:2589–97. doi:10.1056/NEJMoa043623.

    Article  PubMed  CAS  Google Scholar 

  31. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. The Lancet Oncology 2006,7:719–27. doi:10.1016/S1470-2045(06)70804-X.

    Article  PubMed  CAS  Google Scholar 

  32. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008,26:3552–9. doi:10.1200/JCO.2007.13.9030.

    Article  PubMed  Google Scholar 

  33. Lally BE, Detterbeck FC, Geiger AM, et al. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer 2007,110:911–7. doi:10.1002/cncr.22845.

    Article  PubMed  Google Scholar 

  34. Matsuguma H, Nakahara R, Ishikawa Y, et al. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved. Interact Cardiovasc Thorac Surg 2008,7:573–7. doi:10.1510/icvts.2007.174342.

    Article  PubMed  Google Scholar 

  35. Wakelee HA, Stephenson P, Keller SM, et al. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer 2005,48:389–97. doi:10.1016/j.lungcan.2004.11.007.

    Article  PubMed  Google Scholar 

  36. Sawyer TE, Bonner JA, Gould PM, et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 1997,64:1402–7; discussion 7–8. doi:10.1016/S0003-4975(97)00908-9.

    Article  PubMed  CAS  Google Scholar 

  37. Scagliotti GV. The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer. Clin Cancer Res 2005,11:5011s-6s. doi:10.1158/1078-0432.CCR-05-9009.

    Article  PubMed  CAS  Google Scholar 

  38. Wind J, Smit EJ, Senan S, Eerenberg JP. Residual disease at the bronchial stump after curative resection for lung cancer. Eur J Cardiothorac Surg 2007,32:29–34.

    Article  PubMed  Google Scholar 

  39. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2008,6:228–69.

    PubMed  CAS  Google Scholar 

  40. Watanabe Y, Shimizu J, Tsubota M, Iwa T. Mediastinal spread of metastatic lymph nodes in bronchogenic carcinoma. Mediastinal nodal metastases in lung cancer. Chest 1990,97:1059–65. doi:10.1378/chest.97.5.1059.

    Article  PubMed  CAS  Google Scholar 

  41. Kotoulas CS, Foroulis CN, Kostikas K, et al. Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer 2004,44:183–91. doi:10.1016/j.lungcan.2003.10.012.

    Article  PubMed  Google Scholar 

  42. Cerfolio RJ, Bryant AS. Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall-cell lung cancer. Ann Thorac Surg 2006,81:1969–73; discussion 73. doi:10.1016/j.athoracsur.2005.12.067.

    Article  PubMed  Google Scholar 

  43. Kelsey CR, Light KL, Marks LB. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. Int J Radiat Oncol Biol Phys 2006,65:1097–105. doi:10.1016/j.ijrobp.2006.02.007.

    PubMed  Google Scholar 

  44. Senan S, Le Pechoux C, Spoelstra FO, et al. Lack of consensus on post-operative radiotherapy (PORT) fields used in non-small cell lung cancer NSCLC Abstract. Journal of Clinical Oncology 2007,25:7658–00. doi:10.1200/JCO.2006.09.8178.

    Article  Google Scholar 

  45. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991,21:109–22.

    PubMed  CAS  Google Scholar 

  46. Kimsey FC, Mendenhall NP, Ewald LM, et al. Is radiation treatment volume a predictor for acute or late effect on pulmonary function? A prospective study of patients treated with breast-conserving surgery and postoperative irradiation. Cancer 1994,73:2549–55. doi:10.1002/1097-0142(19940515)73:10<2549::AID-CNCR2820731016>3.0.CO;2-N.

    Article  PubMed  CAS  Google Scholar 

  47. Abratt RP, Morgan GW. Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer 2002,35:103–9. doi:10.1016/S0169-5002(01)00334-8.

    Article  PubMed  Google Scholar 

  48. Inoue A, Kunitoh H, Sekine I, et al. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 2001,49:649–55. doi:10.1016/S0360-3016(00)00783-5.

    PubMed  CAS  Google Scholar 

  49. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001,51:650–9. doi:10.1016/S0360-3016(01)01685-6.

    PubMed  CAS  Google Scholar 

  50. Bradley JD, Hope A, El Naqa I, et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys 2007,69:985–92. doi:10.1016/j.ijrobp.2007.04.077.

    PubMed  Google Scholar 

  51. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2006,66:1399–407. doi:10.1016/j.ijrobp.2006.07.1337.

    PubMed  CAS  Google Scholar 

  52. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007,68:94–102. doi:10.1016/j.ijrobp.2006.12.031.

    PubMed  CAS  Google Scholar 

  53. Pan T, Lee TY, Rietzel E, Chen GT. 4D-CT imaging of a volume influenced by respiratory motion on multi-slice CT. Medical physics 2004,31:333–40. doi:10.1118/1.1639993.

    Article  PubMed  Google Scholar 

  54. Maxim PG, Loo BW, Shirazi H, et al. Quantification of motion of different thoracic locations using four-dimensional computed tomography: implications for radiotherapy planning. Int J Radiat Oncol Biol Phys 2007,69:1395–401. doi:10.1016/j.ijrobp.2007.05.016.

    PubMed  Google Scholar 

  55. Keall P, Vedam S, George R, et al. The clinical implementation of respiratory-gated intensity-modulated radiotherapy. Med Dosim 2006,31:152–62.

    Article  PubMed  Google Scholar 

  56. Korreman SS, Juhler-Nøttrup T, Fredberg Persson G, et al. The role of image guidance in respiratory gated radiotherapy. Acta Oncol 2008,47:1390-6. doi:10.1080/02841860802282786.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA

    Yelena Krupitskaya MD

  2. Department of Radiation Oncology, Stanford University, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA

    Billy W. Loo Jr. MD, PhD

Authors
  1. Yelena Krupitskaya MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Billy W. Loo Jr. MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Billy W. Loo Jr. MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krupitskaya, Y., Loo, B.W. Post-Operative Radiation Therapy (PORT) in Completely Resected Non-Small-Cell Lung Cancer. Curr. Treat. Options in Oncol. 9, 343–356 (2008). https://doi.org/10.1007/s11864-009-0090-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-009-0090-8

Search

Navigation